Roswell Park-CIM study shows novel agent can overcome immune dysfunction in cancer

Michael Wong joins Roswell Park as physician-in-chief

Michael Wong joined Roswell Park Comprehensive Cancer Center as the center’s first physician-in-chief.

December 06, 2024

Hemokine modulatory regimen shows promise for TNBC in phase I study

A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.

November 22, 2024

Vol.50 No.44

In Brief

Roswell Park receives $7.7M for biobank

Rep. Tim Kennedy (NY-D) announced $7,731,872 in new federal funding for Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of NIH’s Research Facilities Construction Grants.

October 11, 2024

Vol.50 No.38

In Brief

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Thomas Schwaab was named Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research institute.

September 13, 2024

Vol.50 No.34

Clinical Roundup

Kidney cancers rely on mitochondrial metabolism to metastasize, UTSW study shows

Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.

September 06, 2024

Vol.50 No.33

Clinical Roundup

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

September 06, 2024

Vol.50 No.33

Roswell Park-CIM study shows novel agent can overcome immune dysfunction in cancer

YOU MAY BE INTERESTED IN

Michael Wong joins Roswell Park as physician-in-chief

Hemokine modulatory regimen shows promise for TNBC in phase I study

Roswell Park receives $7.7M for biobank

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Kidney cancers rely on mitochondrial metabolism to metastasize, UTSW study shows

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Renew today!

Subscriber content

Never miss an issue!

Login